Nuvectis Pharma, Inc.
NASDAQ:NVCTBiotechnology
+$0.39 today
- Market cap
- $697.75M
- Beta
- -0.07
- P/E (TTM)
- -11.2
- EPS (TTM)
- -$1.16
Volume 0.19M
Average 0.08M
NVCT Total Assets
Everything the company owns or controls; equal to total liabilities plus equity.
Nuvectis Pharma, Inc.NASDAQ: NVCT
Total Assets · Q1 FY2026 · quarter ended Mar 2026
Total assets falls 15.8% from a year ago
Total assets stood at $25.4M at the end of Q1 FY2026, down 15.8% from a year earlier and down 19.9% from the prior quarter. Over 3 fiscal years it compounded at +15.8% a year.
Context
- Total assets increased in 1 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether total assets keeps falling in the next quarterly balance sheet after a -15.8% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Total Assets history
USD · from the balance sheet
- Latest · FY2025
- 31.71M USD
- Year-over-year change
- +70.4%
- 4-year CAGR
- +47.7%
| Period | Period end | Total Assets | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 31.71M | +70.4% |
| FY2024 | 2024-12-31 | 18.61M | -3.0% |
| FY2023 | 2023-12-31 | 19.19M | -6.0% |
| FY2022 | 2022-12-31 | 20.41M | +206.5% |
| FY2021 | 2021-12-31 | 6.66M | — |
Total Assets vs competitors
How NVCT compares with its peers on the latest reported figures
- NVCT's Mar 2026 total assets of $25.4M is the lowest of the 11 companies compared; the peer median is $332.29M.
- Its year-over-year change of -15.8% is the 9th highest of 11, against a peer median of +35.6%.
- Over three fiscal years its annual growth of +15.8% compares with a peer median of +10.6%.
| Company | Period | Latest balance | YoY | 3-year CAGR |
|---|---|---|---|---|
| Mar 2026 | $214.81B | +423744.3% | +23.8% | |
| Mar 2026 | $1.03B | -2.1% | +40.4% | |
| Jun 2026 | $744.5M | +15.0% | -4.0% | |
| Mar 2026 | $472.67M | -26.2% | +2.1% | |
| Mar 2026 | $436.76M | +79.8% | +18.0% | |
| Mar 2026 | $227.81M | +73.0% | +37.4% | |
| Mar 2026 | $217.87M | -3.0% | -3.9% | |
| Mar 2026 | $205.17M | +56.1% | +3.2% | |
| Mar 2026 | $95.82M | +381.7% | +91.6% | |
| Mar 2026 | $40.61M | -40.6% | -16.0% | |
| Mar 2026 | $25.4M | -15.8% | +15.8% | |
| Peer median (excluding NVCT) | $332.29M | +35.6% | +10.6% | |
Competitors are the stored peer set for NVCT. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Nuvectis Pharma, Inc.
NASDAQ:NVCT
Intrinsic Alpha fair value
Locked
Current Price
$20.29
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.